Gut Microbes Signal Response to Immune Therapy in Melanoma
…Côte d’Azur, European funding FEDER PRIMI and philanthropic contributions from the Lyda Hill Foundation, Dr. Miriam and Sheldon G. Adelson…
Gut Microbes Signal Response to Immune Therapy in Melanoma
…Côte d’Azur, European funding FEDER PRIMI and philanthropic contributions from the Lyda Hill Foundation, Dr. Miriam and Sheldon G. Adelson…
,
,
How Nikki Tichy Used Facebook To Raise Money, Increase Awareness, and Honor Her Friend
…two remained close friends. To read more about Darcy Newton and her courageous battle with melanoma, click {here}. To make a donation…
,
,
President’s Letter | January 2021
…work. The article answers the question, Why Is the Tissue Bank So Important for Melanoma Research? Dr. Kashani-Sabet is the…
,
A Letter From Our Vice President | February 2021
…AIM at Melanoma. Thank you, Melanie. The second story is about melanoma survivor, Mark Lewis, who at 62 years old…
Life After Loss: Lisa Huntley’s Life Has Come Full Circle
…director of the volunteer program at the cancer center. And in 2012, she became Dr. Kirkwood’s administrator in the melanoma…
,
,
Turning Tragedy into Something Positive to Help Others
…them that few people do. Erika—and her memorable laughter and love—passed away on November 15, 2022, at the age of…
,
Long-term Results Continue to Show a Benefit with Nivolumab and Ipilimumab
…approved for use in melanoma, no successful approach to treating advanced melanoma existed. Although chemotherapy has existed for many decades,…
,
You’re Not Out of Options—What To Do After First Line Therapy Fails
…growing field of cell therapy, there are more opportunities than ever to find a treatment that fits your path forward.…
,
Melanoma International Collaborative Adaptive Trials: Progress Report
The first adaptive platform trial in melanoma—and one of the only adaptive platform trials that will be in existence for…
,
,
Tanya Lafontaine, Melanoma Survivor: “I’ve Got This”
…have melanoma, neither should you. Lafontaine was originally diagnosed with Stage II melanoma on July 25, 2016. After the cancer…
,
Recent Posts
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026